Pfizervs.Zoetis
PFE vs ZTS · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Pfizer is about 4.2× larger than Zoetis by market cap; Zoetis trades at the lower P/E (12.4 vs 18.5); year to date, Pfizer leads (−2.9% vs −39.9%).
Side by side
| PFE | ZTS | |
|---|---|---|
| Market cap | $138B | $32.9B |
| Price | $24.17 | $75.56 |
| Today | −0.3% | +0.6% |
| Return YTD | −2.9% | −39.9% |
| Return 1Y | −6.2% | −52.4% |
| P/E | 18.5 | 12.4 |
| P/S | 2.2 | 3.5 |
| P/B | 1.5 | 10.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
PfizerPFE
Large American pharmaceutical group with a broad portfolio in vaccines, oncology and internal medicine.
Full PFE profile →ZoetisZTS
The world’s largest animal health company — medicines and vaccines for pets and livestock, spun off from Pfizer in 2013.
Full ZTS profile →More comparisons in Big pharma
See where PFE and ZTS sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →